ClinicalTrials.gov
ClinicalTrials.gov Menu

Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02635256
Recruitment Status : Recruiting
First Posted : December 18, 2015
Last Update Posted : November 22, 2018
Sponsor:
Collaborators:
University of Luebeck
Saphir Radiosurgery Center Northern Germany
Information provided by (Responsible Party):
Juergen Dunst, Prof., University of Schleswig-Holstein

Brief Summary:

Hypofractionated radiosurgery has been investigated in a few trials and appears to be safe and feasible.

Investigators initiated this multicenter phase II prospective trial to analyse feasibility (toxicity) of hypofractionated radiosurgery with 5 fractions in patients with localised prostate cancer, who are ineligible for the "PREFERE trial" under the hypothesis that the ratio of patients with late toxicity ≥ grade 2 after 1 year amounts 2,8% and is significant lower than 17.5%.


Condition or disease Intervention/treatment Phase
Prostate Cancer Radiation: Hypofractionated Radiosurgery Not Applicable

Detailed Description:

Experimental radiosurgery of prostate with 5 fractions each with 7,00 Gy (total application rate of 35,00 Gy).

Planned visits are: Baseline, visits at every radiation day and four follow ups (4-6 weeks, 3 months, 6 months and one year after last day of radiation).


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 85 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hypofractionated Radiosurgery for Localised Prostate Cancer
Actual Study Start Date : December 2015
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Hypofractionated Radiosurgery
5 fractions with 7 Gy, total dose 35 Gy
Radiation: Hypofractionated Radiosurgery
Image-guided stereotactic Linac based RT preferable with "dedicated radiosurgery system" such as CyberKnife




Primary Outcome Measures :
  1. Late toxicity measured with Radiation Therapy Oncology Group-(RTOG)-Score [ Time Frame: 12-15 months after radiotherapy ]

Secondary Outcome Measures :
  1. Acute toxicity analysed by Adverse Event (AE)- and Serious Adverse Event (SAE)-reports. [ Time Frame: through study completion ]
  2. Prostate Specific Antigen (PSA) [ Time Frame: At the time of inclusion and 1, 3, 6-9 and 12-15 months after radiotherapy ]
  3. International Prostate Symptom Score (IPSS) [ Time Frame: Screening and 3, 6-9 and 12-15 months after radiotherapy ]
  4. EORTC Quality of Life Questionnaire (QLQ) C30 [ Time Frame: At the time of inclusion and 12-15 months after radiotherapy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Localised, histopathologically confirmed Prostate Cancer (cT1-3 N0 M0)
  • Gleason-grade ≤7
  • Guideline-based staging
  • Age ≥ 60 years
  • PSA < 15 ng/ml
  • Volume of the prostate <80 cm³
  • IPSS-Score ≤12
  • Written informed consent

Exclusion Criteria:

  • History of prior pelvic radiotherapy
  • Contraindication to MRI or Fiducial marker implantation (e.g. allergy to gold),
  • Immunosuppressive therapy
  • Relevant comorbidity thought to adversely affect treatment compliance,
  • Legal incapacity or lack of informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02635256


Contacts
Contact: Juergen Dunst, Prof. 0049/431/500 ext 26501 Juergen.Dunst@uksh.de
Contact: Oliver Blanck, Dr. 0049/3843/34599 ext 0 blanck@saphir-rc.com

Locations
Germany
Saphir Radiosurgery Center Frankfurt am Main Active, not recruiting
Frankfurt am Main, Germany, 60528
University Hospital Frankfurt, Department of Radiation Therapy and Oncology Recruiting
Frankfurt am Main, Germany, 60590
Principal Investigator: Christian Keller, MD         
Sub-Investigator: Panagiotis Balermpas, MD         
Saphir Radiosurgery Center Northern Germany Active, not recruiting
Güstrow, Germany, 18273
University Medical Center Schleswig-Holstein Recruiting
Kiel, Germany, 24105
Principal Investigator: Juergen Dunst, Prof.         
Sub-Investigator: Karen Huber, MD         
Sub-Investigator: Rene Baumann, MD         
European Cyberknife Center Munich Recruiting
Munich, Germany, 81377
Principal Investigator: Alexander Muacevic, Prof. Dr.         
Sub-Investigator: Cristopf Fürweger, MD         
Sponsors and Collaborators
University of Schleswig-Holstein
University of Luebeck
Saphir Radiosurgery Center Northern Germany
Investigators
Principal Investigator: Juergen Dunst, Prof. University of Schleswig-Holstein

Publications:
Responsible Party: Juergen Dunst, Prof., Prof. Dr. med. Juergen Dunst, University of Schleswig-Holstein
ClinicalTrials.gov Identifier: NCT02635256     History of Changes
Other Study ID Numbers: ZKS-121-003
ARO-2016-5 ( Other Identifier: German Cancer Society )
First Posted: December 18, 2015    Key Record Dates
Last Update Posted: November 22, 2018
Last Verified: November 2018

Keywords provided by Juergen Dunst, Prof., University of Schleswig-Holstein:
hypofractionation
prostate cancer
radiotherapy

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases